Improved results from cellular therapies thanks to AI and bioinformatic platforms
Positive signals from early-phase studies suggest that newer molecular technologies may help to disclose the promises of T-cell therapies in different settings
Transforming cancer care through collaborative research
Successful partnerships between industry and academia has had a positive impact on cancer drug discovery and development in prostate cancer
Study provides new evidence linking air pollution with increased breast cancer risk
Epidemiological data from France underline the urgent need for public policy and advocacy to improve air quality around the world
Invasive breast cancer: can surgery be eliminated after neoadjuvant systemic chemotherapy?
Phase II data report a pathologic complete response in patients who received radiotherapy after neoadjuvant therapy without surgery, when selected by image-guided vacuum-assisted core biopsy
Sustained efficacy of CDK inhibitors reported for HR+/HER2– early breast cancer
Long-term data from monarchE supports dose reduction while NATALEE data reinforces consistency across subgroups
Aspirin in colorectal cancer – has it still a place in secondary prevention?
Negative results from the ASCOT trial should not discourage researchers from investigating the drug’s potential in some molecularly distinct subgroups
Studies confirm the promise of ctDNA for MRD assessment in colorectal cancer, but limitations remain
Despite positive results from trials, the use of different assays with variable sensitivities and specificities impact their interpretation and clinical validation
Tebentafusp shows sustained benefit only in a small proportion of patients with metastatic uveal melanoma
Novel targeted strategies are investigated in uveal melanoma, especially for those who do not respond to the bispecific fusion protein, with some encouraging early-phase data from c-MET/PKC inhibitors
Induction chemotherapy before CRT improves outcomes in locally advanced cervical cancer
Phase III trial findings reveal significant improvements in PFS and OS rates, although the population studied may not be wholly indicative of high-risk disease
Combination therapies with immunotherapy and ADCs prolong overall survival in urothelial carcinoma
Positive outcomes in advanced or metastatic disease reported from EV-302/KEYNOTE-A39 and CheckMate 901 indicate an alternative to first-line chemotherapy for the first time